Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

ClinicalTrials.gov ID: NCT05223699

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05223699. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II, Dose-Escalation Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This research study is designed to selectively deplete CD117-positive cells from participants with AML and MDS-EB.

Study identification

NCT ID: NCT05223699
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Magenta Therapeutics, Inc.; Industry
Enrollment: 22 participants

Conditions and interventions

Conditions

Interventions

MGTA-117 Biological

Biological

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 14, 2022 (Actual)
Primary completion: Feb 2, 2023 (Actual)
Completion: Feb 2, 2023 (Actual)
Last update posted: Feb 9, 2023

2022 – 2023

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	—
Sarah Cannon Research Institute at HealthONE	Denver	Colorado	80218	—
Moffitt Cancer Center	Tampa	Florida	33612	—
The University of Kansas Cancer Center	Westwood	Kansas	66205	—
University of Minnesota	Minneapolis	Minnesota	55455	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Roswell Park Comprehensive Cancer Center	Buffalo	New York	14203	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05223699, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 9, 2023 · Synced Nov 13, 2026